The Caenorhabditis elegans DPF-3 and human DPP4 have tripeptidyl peptidase activity. [PDF]
FEBS LettThe dipeptidyl peptidase IV (DPPIV) family comprises serine proteases classically defined by their ability to remove dipeptides from the N‐termini of substrates, a feature that gave the family its name. Here, we report the discovery of a previously unrecognized tripeptidyl peptidase activity in DPPIV family members from two different species.
Trivedi A, Gudipati RK.
europepmc +2 more sources
Evaluation of cardioprotective effects of the incritinmimetics exenatideand vildagliptin in the experiment [PDF]
, 2017 The results of experimental and clinical trials make it clear that incretin mimetics possess pleiotropic effects and demonstrate the value in terms of assessment of their potential opportunities as cardioprotectors.
Danilenko, L. M. +4 more
core +2 more sources
Biomedicines, 2023 The repurposing of drugs is one of the most competent strategies for discovering new antimicrobial agents. Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPI-4) that is used effectively in combination with metformin to control blood glucose levels ...
Maan T. Khayat +7 more
doaj +1 more source
A Prospective Observational Study to Compare the Efficacy and Adverse Effects of Glimepiride and Vildagliptin Added to Metformin in Type 2 Diabetes Mellitus [PDF]
Journal of Clinical and Diagnostic Research, 2019 Introduction: In order to prevent the specific diabetes mellitus related macrovascular and microvascular complications, guidelines by American Diabetes Association recommend a reasonable glycosylated haemoglobin goal for non-pregnant adults to be less ...
Biswanath Sharma Sarkar +3 more
doaj +1 more source
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]
, 2017 Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu +4 more
core +5 more sources
International Journal of Endocrinology, 2015 The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy.
Andrea Tura +5 more
doaj +1 more source
Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients
Frontiers in Endocrinology, 2021 Background and aimsAnimal studies suggested that vildagliptin might exert a beneficial effect on cognitive function. The present study evaluated whether the use of vildagliptin in patients with type 2 diabetes mellitus might affect dementia risk ...
Chin-Hsiao Tseng +2 more
doaj +1 more source
Childhood cancer in Iceland 1981-2006 [PDF]
, 2010 Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn Skoða/Opna(view/open)BACKGROUND: Childhood cancer is the second most common cause of death in children. The aim of this study was to gather epidemiological information
Guðmundur K. Jónmundsson +5 more
core +1 more source
Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]
, 2014 The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen +58 more
core +3 more sources
The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses [PDF]
, 2014 Inhibitors of dipeptidylpeptidase IV (DPP-IV) represent a novel class of frequently used anti-diabetic drugs. In addition to its function in metabolic regulation, DPP-IV also plays a role in the immune system.
Buhling +11 more
core +1 more source